引用次数
引用: 106,047
H-指数: 120
I10-指数 : 552
出版物: 1,504
Tratamiento de quimioterapia del cáncer avanzado de vejiga
Luis Paz-Ares , S. Neciosup
Revisiones en cáncer 19 ( 3) 153 -162
2005
Envolving treatment of fever and neutropenia in cancer patients
Alfonso Sánchez-Muñoz , Rocío García-Carbonero , Hernán Cortés-Funes , Luis Paz-Ares
Clinical & Translational Oncology 4 ( 6) 297 -307
1
2002
Microrna expression model as a survival indicator in patients having metastatic colorectal cancer
Luis Gonzalo Paz-Ares , Amancio Carnero Moya , Sonia Molina Pinelo , Rocío García Carbonero
2013
Pemetrexed Combined with Oxaliplatin or Carboplatin as First-Line Treatment in Advanced Non–Small Cell Lung Cancer: A Multicenter, Randomized, Phase II Trial
Giorgio V Scagliotti , Cornelius Kortsik , Graham G Dark , Allan Price
Clinical Cancer Research 11 ( 2) 690 -696
119
2005
Necitumumab for first-line treatment of advanced, squamous, non-small-cell lung cancer: a relevant step forward?
Jon Zugazagoitia , Santiago Ponce , Luis Paz-Ares ,
Translational lung cancer research 5 ( 1) 95 -97
8
2016
Efficacy and safety of necitumumab continuation therapy in phase 3 SQUIRE study
C Obasaju , L Paz-Ares , A Kazarnowicz , H Depenbrock
Journal of Thoracic Oncology
2015
RandomizedPhaseIIIStudyComparingPaclitaxel/Cisplatin/ GemcitabineandGemcitabine/CisplatininPatientsWithLocally AdvancedorMetastaticUrothelialCancerWithoutPriorSystemic Therapy:EORTCIntergroupStudy30987
Sandrine Marreaud , Luis Paz-Ares , Iwona Skoneczna , Sandra Collette
2012
EGFR IHC and FISH Correlative Analyses (SQUIRE Trial): necitumumab plus gemcitabine-cisplatin vs gemcitabine-cisplatin in 1st-line squamous NSCLC
L Paz-Ares , Nick Thatcher , R Hozak , C Caldwell
3
2015
Pemetrexed plus cisplatin (P plus CIS) or carboplatin (P plus CB) in chemonaive malignant pleural mesothelioma (MPM) patients (PTS): Results of the international expanded access program (EAP)
L Paz-Ares , J Blatter , S Sundstrom , Kristiaan Nackaerts
Annals of Oncology 18 32 -32
1
2007
A RANDOMIZED, PHASE 2 STUDY OF PACLITAXEL (P) AND CARBOPLATIN (C) +/- CONATUMUMAB (CON) FOR FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC)
L. Paz-Ares , J. P. van Meerbeeck , V. Haddad , R. Wierzbicki
Annals of Oncology 21
3
2010
International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers
G Pizzocaro , L PazAres , DF Bajorin , G Daugaard
Journal of Clinical Oncology 15 ( 2) 594 -603
1,013
1997
440O Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm +) NSCLC: overall survival (OS) sdata from LUX-Lung 7 (LL7)
K Park , EH Tan , L Zhang , V Hirsh
Annals of Oncology 27
1
2016
Nivolumab in patients with previously treated metastatic squamous non-small cell lung cancer (NSCLC): results of a European single-arm, phase II trial (CHECKMATE 171) including patients aged >= 70 years or with poor performance status.
J Jassem , L Paz-Ares , M Szilasi , J Van Meerbeeck
2017
Rash as a marker for the efficacy of necitumumab in the SQUIRE Study
P Bonomi , Patrick Peterson , M Socinski , Martin Reck
1
2015
Brigatinib in Crizotinib-Refractory ALK plus NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial
Marcello Tiseo , Luis Paz-Ares , Harry Groen , Maximilian Hochmair
Journal of Thoracic Oncology 12 ( 1)
1
2017
Three-year overall survival update from the PACIFIC trial.: 2018 ASCO Annual Meeting Abstracts
Jhanelle Elaine Gray , Augusto E Villegas , Davey B Daniel , David Vicente
2019
Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC): overall survival (OS) data from the phase IIb trial LUX-Lung 7 (LL7) (Conference Abstract)
Luis Paz-Ares , Ken O'Byrne , Vera Hirsh , Eng-Huat Tan
Annals of Oncology
1
2016
Entrectinib in patients with NTRK fusion-positive solid tumors or ROS1-positive NSCLC with CNS metastases
G Demetri , R Doebele , L Paz-Ares , AT Shaw
2020
Rechallenge with Immunotherapy in Small Cell Lung Cancer andndash; A Case Report
Luis Paz-Ares , Santiago Ponce-Aix , Nerea Muñoz Unceta , Ana Sánchez de Torre
Clinical Case Reports 9 ( 10) 1 -6
2019
Treatment rationale study design for the MetLung trial : a randomized, double-blind phase III study of onartuzumab (MetMAb) in combination with erlotinib versus erlotinib alone in patients who have received standard chemotherapy for stage IIIB or IV
Tony Mok , Luis Paz-Ares , Kenneth O'Byrne , David Spigel
Clinical Lung Cancer
2012